Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor

Swati Sikaria, Josefine Heim-Hall, Elizabeth H. Diaz, Ronald Williams, Kamelesh Sankhala, Brenda Laabs, Monica Mita

Research output: Contribution to journalArticle

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)73-79
Number of pages7
JournalTargeted Oncology
Volume9
Issue number1
DOIs
StatePublished - Mar 2014

Keywords

  • IGFR inhibitor
  • Tenosynovial giant cell tumor
  • mTOR inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this